EATG » Pharma industry

Pharma industry

Ireland: Gilead withdraws challenge to generic HIV drug

Gilead has dropped its appeal against the High Court’s refusal to grant an injunction against generic manufacturers Pharmaceutical giant Gilead, which manufactures the HIV anti-retroviral drug Truvada, has withdrawn its…

EFGCP Conference Coming Up in February

The upcoming conference of the European Forum for Good Clinical Practice holds its next conference in Brussels in February 2018. The conference will pay special attention to the consequences of…

This company is about to flood the US with cheap HIV drugs

India’s Laurus Labs preparing to enter U.S. with HIV generics Patents on key branded medicines to start expiring soon December 4, 2017 - Among the coconut plantations and beaches of…

EMA: Regulatory guidance for pharmaceutical companies to prepare for UK’s withdrawal from EU

EMA and European Commission publish updated Q&As The European Medicines Agency (EMA) and the European Commission have published additional guidance to help pharmaceutical companies prepare for the United Kingdom’s withdrawal…

EMA: Guidance to help pharma companies prepare for Brexit

Additional guidance relates to medicines for human and veterinary use The European Medicines Agency (EMA) has published additional guidance to help pharmaceutical companies prepare for the United Kingdom’s (UK) withdrawal…

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines after Brexit

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit The associations representing…

EFPIA guidance document on interaction with patient organisations

The European Federation of Pharmaceutical Industries and Associations (EFPIA) released a new guidance, Working together with patient groups. The aim of the document is to underline the rationale for interactions…

Pills and Profits: How drug companies make a killing out of public research

In this joint report, STOPAIDS and Global Justice Now show how taxpayers are funding billions of pounds worth of research into life-changing drugs – only to be told they are…

Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases

Agreement includes investigational RNAi therapeutic program for hepatitis B virus infection and discovery collaboration on additional development candidates for treatment of infectious diseases CAMBRIDGE, Mass., 18 October 2017 -- Alnylam…

Janssen to discontinue hepatitis C development program

Viral hepatitis research and development to focus on addressing significant unmet needs in chronic hepatitis B  CORK, Ireland, September 11, 2017 - Janssen Sciences Ireland UC (Janssen), today announced a strategic decision…

1 2 3 5